4-溴-2-甲氧基苯甲酰胺 | 812667-44-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-溴-2-甲氧基苯甲酰胺
• 英文名称: 4-bromo-2-methoxybenzamide
• CAS: 812667-44-0
• 化学式: C₈H₈BrNO₂
• mdl: MFCD12913570
• 分子量: 230.061
• InChiKey: IVYKCTGCJDBWMQ-UHFFFAOYSA-N

物化性质

• 沸点：
  305.9±32.0 °C(Predicted)
• 密度：
  1.551±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Bromo-2-methoxybenzamide
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Bromo-2-methoxybenzamide
CAS number: 812667-44-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H8BrNO2
Molecular weight: 230.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-溴-2-甲氧基苯甲酰胺 在 三氟甲磺酸 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 以92%的产率得到4-溴-2-甲氧基苯腈
  参考文献：
  名称：

  [EN] IMIDAZOTRIAZINONE DERIVATIVES AS PDE 7 (PHOSPHODIESTERASE 7) INHIBITORS
  [FR] DERIVES D'IMIDAZOTRIAZINONE SERVANT D'INHIBITEURS DE PDE 7 (PHOSPHODIESTERASE 7)

  摘要：

  本发明提供了选择性抑制PDE 7的化合物，从而增强细胞内cAMP水平。因此，该化合物对治疗各种疾病如过敏性疾病、炎症性疾病或免疫性疾病具有用处。该化合物是由以下式(IA)或(IB)表示的咪唑并吡嗪酮化合物：特别地，R1是环己基，R2是甲基；R3是氢原子；硝基；氰基；卤原子；杂环烷基；取代或未取代的C1-C6烷基；取代或未取代的C2-C6烯基；取代或未取代的饱和或不饱和杂环烷基；一个基团：-NR5R6，-C(O)R7，-SO2R7，-OR8，-NR8COR7，-NR8SO2R7；A是CR4；B是CH。

  公开号：

  WO2004111053A1
• 作为产物：
  描述：

  4-溴-2-甲氧基苯腈 在 水 、 potassium hydroxide 作用下， 以 乙醇 为溶剂， 反应 24.0h， 以30%的产率得到4-溴-2-甲氧基苯甲酰胺
  参考文献：
  名称：

  [EN] 4, 5-DIHYDRO-1H-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES
  [FR] COMPOSÉS 4,5-DIHYDRO-LH-PYRAZOLE ET LEURS UTILISATIONS PHARMACEUTIQUES

  摘要：

  公开号：

  WO2010116282A8

文献信息

• Substituted Pyrrolidine-2-Carboxamides
  申请人：Ding Qingjie

  公开号：US20100075948A1

  公开（公告）日：2010-03-25

  There are provided compounds of the formula wherein X, Y, R 1 , R 2 , R 3 , R 3 , R 4 , R 5 , R 6 and R 7 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.

  提供了以下式的化合物 其中X、Y、R1、R2、R3、R3、R4、R5、R6和R7如本文所述，以及其对映体和药用可接受的盐和酯。这些化合物可用作抗癌药物。
• Explicit treatment of active-site waters enhances quantum mechanical/implicit solvent scoring: Inhibition of CDK2 by new pyrazolo[1,5-a]pyrimidines
  作者：Michaela Hylsová、Benoit Carbain、Jindřich Fanfrlík、Lenka Musilová、Susanta Haldar、Cemal Köprülüoğlu、Haresh Ajani、Pathik S. Brahmkshatriya、Radek Jorda、Vladimír Kryštof、Pavel Hobza、Aude Echalier、Kamil Paruch、Martin Lepšík

  DOI：10.1016/j.ejmech.2016.12.023

  日期：2017.1

  affinities. To this aim, we prepared 21 new inhibitors of cyclin-dependent kinase 2 (CDK2) with the pyrazolo[1,5-a]pyrimidine core, whose activities spanned three orders of magnitude. The crystal structure of a potent inhibitor bound to the active CDK2/cyclin A complex revealed that the biphenyl substituent at position 5 of the pyrazolo[1,5-a]pyrimidine scaffold was located in a previously unexplored

  我们目前在基于量子力学（QM）的蛋白质-配体亲和力评分中对溶剂表示形式进行全面测试。为此，我们用吡唑并[1,5- a ]嘧啶核心制备了21种新的细胞周期蛋白依赖性激酶2（CDK2）抑制剂，其活性跨越了三个数量级。与活性CDK2 / cyclin A复合物结合的强效抑制剂的晶体结构表明，吡唑并[1,5- a] 5位的联苯取代基] pyrimidine支架位于以前未开发的口袋中，六个水分子位于活性位点。使用分子动力学，蛋白质-配体相互作用和活性位点水H键网络以及热力学进行了探讨。此后，使用COSMO隐式溶剂模型通过QM方法对所有抑制剂进行评分。这样的标准处理未能与实验产生相关性（R 2  = 0.49）。但是，添加活动场所水带来了显着的改善（R 2 = 0.68）。因此，可以通过考虑化合物与CDK2和活性位点水的特定非共价相互作用来解释化合物的活性。总而言之，结合多种实验方法和理论方法，我们证明了显式溶剂作用的加入增强了QM
• Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase
  作者：Kevin S. Currie、Jeffrey E. Kropf、Tony Lee、Peter Blomgren、Jianjun Xu、Zhongdong Zhao、Steve Gallion、J. Andrew Whitney、Deborah Maclin、Eric B. Lansdon、Patricia Maciejewski、Ann Marie Rossi、Hong Rong、Jennifer Macaluso、James Barbosa、Julie A. Di Paolo、Scott A. Mitchell

  DOI：10.1021/jm500228a

  日期：2014.5.8

  expected that a more selective Syk inhibitor would provide a greater therapeutic window. Herein we report the discovery and optimization of a novel series of imidazo[1,2-a]pyrazine Syk inhibitors. This work culminated in the identification of GS-9973, 68, a highly selective and orally efficacious Syk inhibitor which is currently undergoing clinical evaluation for autoimmune and oncology indications.

  脾酪氨酸激酶（Syk）在自身免疫，炎症和肿瘤疾病适应症中是有吸引力的药物靶标。最先进的Syk抑制剂，R406，1（或它的前药形式fostamatinib，2），已在多个治疗适应症中显示出功效，但其临床进展已经由已被归因，至少部分剂量限制性不利影响的阻碍，到的脱靶活性1。预期选择性更高的Syk抑制剂将提供更大的治疗窗口。在本文中，我们报告了一系列新型咪唑并[1,2- a ]吡嗪Syk抑制剂的发现和优化。这项工作在GS-9973，鉴定高潮68是一种高度选择性和口服有效的Syk抑制剂，目前正在针对自身免疫和肿瘤学适应症进行临床评估。
• [EN] ANTIBACTERIAL BIAROMATIC DERIVATIVES<br/>[FR] DÉRIVÉS BI-AROMATIQUES ANTIBACTÉRIENS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2014170821A1

  公开（公告）日：2014-10-23

  The invention relates to antibacterial compounds of formula I (I) wherein R is H, cyano, alkoxy, cyanomethoxy, cycloalkylmethoxy, hydroxyalkoxy, alkoxyalkoxy, alkoxycarbonyl, 2-ethoxy-2-oxoethoxy, 2-(methylamino)-2-oxoethoxy, (l-cyanocyclobutyl)methoxy, 3-hydroxy-pyrrolidin-l-yl or 3,4-dihydroxycyclopentyl)methoxy; U1 is N or CR1, U2 is N or CR2, U3 is N or CR3 and U4 is N or CR4, it being understood that at most three of U1, U2, U3 and U4 can be N at the same time; V1 is N or CR5, V2 is N or CR6, V3 is N or CR7 and V4 is N or CH, it being understood that at most two of V1, V2, V3 and V4 can be N at the same time; R1 is H, cyano, hydroxy or alkoxy; R2 is H, hydroxy or alkoxy; R3 is H, cyano, hydroxy, alkoxy or carboxamido; R4 is H or alkoxy; R5 is H, hydroxy or halogen; R6 is H, hydroxy or halogen; R7 is H; the dotted line "_____ " represents a bond or is absent; W represents CH or N when the dotted line "_____ " is a bond, or W represents CH2 when the dotted line "_____ " is absent; X represents CH or N; and Q represents O or S; and salts thereof.

  该发明涉及公式I（I）的抗菌化合物，其中R是H、氰基、烷氧基、氰甲氧基、环烷基甲氧基、羟基烷氧基、烷氧基烷氧基、烷氧基羰基、2-乙氧基-2-氧基乙氧基、2-(甲基氨基)-2-氧基乙氧基、(1-氰基环丁基)甲氧基、3-羟基吡咯烷-1-基或3,4-二羟基环戊基)甲氧基；U1是N或CR1，U2是N或CR2，U3是N或CR3，U4是N或CR4，理解为U1、U2、U3和U4中最多有三个可以同时为N；V1是N或CR5，V2是N或CR6，V3是N或CR7，V4是N或CH，理解为V1、V2、V3和V4中最多有两个可以同时为N；R1是H、氰基、羟基或烷氧基；R2是H、羟基或烷氧基；R3是H、氰基、羟基、烷氧基或羧胺基；R4是H或烷氧基；R5是H、羟基或卤素；R6是H、羟基或卤素；R7是H；虚线"_____"代表键或不存在；W代表CH或N，当虚线"_____"为键时，或W代表CH2，当虚线"_____"不存在时；X代表CH或N；Q代表O或S；及其盐。
• [EN] IMIDAZOTRIAZINONE DERIVATIVES AS PDE 7 (PHOSPHODIESTERASE 7) INHIBITORS<br/>[FR] DERIVES D'IMIDAZOTRIAZINONE SERVANT D'INHIBITEURS DE PDE 7 (PHOSPHODIESTERASE 7)
  申请人：DAIICHI SUNTORY PHARMA CO LTD

  公开号：WO2004111053A1

  公开（公告）日：2004-12-23

  The present invention provides the compounds inhibiting PDE 7 selectively, and therefore, enhances cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic disease, inflammatory disease or immunologic disease. The compound is imidazotirazinone compound represented by the following formula (IA) or (IB): especially, R1 is cyclohexyl group, R2 is methyl group; R3 is a hydrogen atom; nitro group; cyano group; a halogen atom; heteroaryl group; substituted or unsubstituted C1-C6 alkyl group; substituted or unsubstituted C2-C6 alkenyl group; saturated or unsaturated heterocycloalkyl group which is substituted or unsubstituted; a group: -NR5R6, -C(O)R7, -SO2R7, -OR8, -NR8COR7, -NR8SO2R7; A is CR4; and B is CH.

  本发明提供了选择性抑制PDE 7的化合物，从而增强细胞内cAMP水平。因此，该化合物对治疗各种疾病如过敏性疾病、炎症性疾病或免疫性疾病具有用处。该化合物是由以下式(IA)或(IB)表示的咪唑并吡嗪酮化合物：特别地，R1是环己基，R2是甲基；R3是氢原子；硝基；氰基；卤原子；杂环烷基；取代或未取代的C1-C6烷基；取代或未取代的C2-C6烯基；取代或未取代的饱和或不饱和杂环烷基；一个基团：-NR5R6，-C(O)R7，-SO2R7，-OR8，-NR8COR7，-NR8SO2R7；A是CR4；B是CH。